IRIS
SILVESTRIS, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.747
AS - Asia 5.827
EU - Europa 4.403
SA - Sud America 1.641
Continente sconosciuto - Info sul continente non disponibili 596
AF - Africa 281
OC - Oceania 8
AN - Antartide 1
Totale 31.504
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.425
SG - Singapore 2.572
IT - Italia 1.419
BR - Brasile 1.277
CN - Cina 993
HK - Hong Kong 757
SE - Svezia 733
RU - Federazione Russa 597
FR - Francia 430
VN - Vietnam 372
GB - Regno Unito 293
DE - Germania 267
IN - India 227
BD - Bangladesh 213
CA - Canada 152
FI - Finlandia 127
BE - Belgio 112
AR - Argentina 106
TR - Turchia 101
ID - Indonesia 82
MX - Messico 79
IQ - Iraq 78
ZA - Sudafrica 78
CO - Colombia 75
UA - Ucraina 68
JP - Giappone 59
CI - Costa d'Avorio 58
EC - Ecuador 58
VE - Venezuela 53
PK - Pakistan 52
PL - Polonia 49
ES - Italia 47
CZ - Repubblica Ceca 39
SA - Arabia Saudita 33
NL - Olanda 31
AT - Austria 30
UZ - Uzbekistan 29
MY - Malesia 28
MA - Marocco 25
AE - Emirati Arabi Uniti 24
IE - Irlanda 20
KE - Kenya 20
PH - Filippine 20
CL - Cile 19
ET - Etiopia 19
JO - Giordania 18
LT - Lituania 18
NP - Nepal 18
IL - Israele 17
BG - Bulgaria 15
BO - Bolivia 15
DZ - Algeria 15
IR - Iran 15
CR - Costa Rica 14
JM - Giamaica 14
TN - Tunisia 14
CH - Svizzera 13
EG - Egitto 13
PY - Paraguay 13
RS - Serbia 11
UY - Uruguay 11
HN - Honduras 10
KR - Corea 10
PT - Portogallo 10
HR - Croazia 9
KZ - Kazakistan 9
PE - Perù 9
QA - Qatar 9
SY - Repubblica araba siriana 9
TH - Thailandia 9
AZ - Azerbaigian 8
BH - Bahrain 8
KW - Kuwait 8
RO - Romania 8
DO - Repubblica Dominicana 7
KG - Kirghizistan 7
LY - Libia 7
NI - Nicaragua 7
PA - Panama 7
TT - Trinidad e Tobago 7
AL - Albania 6
DK - Danimarca 6
HU - Ungheria 6
LB - Libano 6
PS - Palestinian Territory 6
BY - Bielorussia 5
LV - Lettonia 5
NO - Norvegia 5
SR - Suriname 5
AO - Angola 4
AU - Australia 4
GE - Georgia 4
GT - Guatemala 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
SV - El Salvador 4
AM - Armenia 3
BB - Barbados 3
BW - Botswana 3
GR - Grecia 3
Totale 30.828
Salva come PNG Salva come JPEG
Città #
Ashburn 2.175
Fairfield 2.038
Chandler 1.749
Singapore 1.438
Woodbridge 1.025
San Jose 952
Seattle 918
Cambridge 902
Houston 853
Hong Kong 750
Wilmington 651
Milan 593
Nyköping 560
Ann Arbor 394
Beijing 394
Council Bluffs 394
Dallas 329
Los Angeles 292
New York 271
Lawrence 243
Lauterbourg 233
Roxbury 228
Rome 208
Des Moines 149
Santa Clara 138
Columbus 125
The Dalles 119
Ho Chi Minh City 112
Brussels 110
Paris 108
Brooklyn 106
São Paulo 104
San Diego 98
Inglewood 91
Dearborn 90
Chicago 88
Hanoi 86
Munich 86
London 85
Jacksonville 80
Helsinki 78
Moscow 74
Atlanta 71
San Francisco 71
Boardman 67
Denver 66
Phoenix 61
Abidjan 58
Pune 57
Tokyo 56
Figino 55
Bari 54
Frankfurt am Main 54
Montreal 53
Buffalo 51
Orem 48
Jakarta 45
Rio de Janeiro 42
Turin 42
Warsaw 41
Nanjing 40
Washington 37
Chennai 33
Johannesburg 32
Baghdad 29
Mexico City 29
Turku 28
Toronto 27
Belo Horizonte 26
Brasília 26
Brno 26
San Mateo 26
Tashkent 26
Ankara 25
Edinburgh 25
Falkenstein 25
Boston 24
Da Nang 23
Falls Church 23
Guangzhou 23
Porto Alegre 23
Princeton 23
Campinas 22
Dong Ket 22
Stockholm 22
Istanbul 21
Poplar 21
Shanghai 21
Vienna 21
Amsterdam 20
Bologna 20
Dublin 20
Guayaquil 20
Jinan 20
Ruvo Di Puglia 20
Quito 19
Charlotte 18
Mumbai 18
Addis Ababa 17
Bogotá 17
Totale 21.467
Salva come PNG Salva come JPEG
Nome #
Molecularly targeted endocrine therapies for breast cancer 1.022
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 395
Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity 265
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 259
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 235
Angiogenesis in adenosquamous cancer of pancreas 229
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells 211
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 193
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study 189
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 187
Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma 186
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 179
Targeting angiogenesis in biliary tract cancers: An open option 178
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 175
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 175
NHERF1 and tumor microenvironment: A new scene in invasive breast carcinoma 174
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence 169
Adjuvant colon cancer chemotherapy: Where we are and where we'll go 169
Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence 168
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 166
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 165
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 165
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 165
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 163
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 163
Bone metastases in biliary cancers: A multicenter retrospective survey 163
Carcinogenesis of pancreatic adenocarcinoma: Precursor lesions 162
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 162
The European accreditation of Istituto Tumori Giovanni Paolo II of Bari 161
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 161
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 160
Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis with a focus on epithelial to mesenchymal transition 159
[Apoptosis or programmed cell death: regulatory and pathophysiological mechanisms]. FT Apoptosi, o morte cellulare programmata: meccanismi regolatori e fisiopatologia. 158
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 157
Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study 156
mTOR as a target of everolimus in refractory/relapsed Hodgkin Lymphoma 154
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 153
Should tumor infiltrating lymphocytes, androgen receptor, and FOXA1 expression predict the clinical outcome in triple negative breast cancer patients? 152
Challenges and opportunities of MicroRNAs in lymphomas 152
The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy 152
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity 151
Synthetic lethality to overcome cancer drug resistance 150
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 150
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 149
Adjuvant therapy in colon cancer 148
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside 148
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 148
Co-expression of CD133+/CD44+ in human colon cancer and liver metastasis 146
Combined modality treatments in pancreatic cancer 145
Molecular classifications of gastric cancers: Novel insights and possible future applications 145
Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype 145
Target therapies in pancreatic carcinoma 145
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 144
IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity 143
Immunotherapeutic approaches for hepatocellular carcinoma 143
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 143
How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis 143
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 142
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 142
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: From biological principles to clinical guidelines 141
Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: The gastric life nomogram 141
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 141
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer 141
Oncosuppressor methylation: A possible key role in colon metastatic progression 141
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 141
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 141
Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine 141
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 140
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 140
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 140
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 139
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 139
New molecular targets in bone metastases 139
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 138
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: An open issue 138
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 137
Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey 137
A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery 136
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 135
HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives 135
p53 as the main traffic controller of the cell signaling network 135
Actors on the scene: Immune cells in the myeloma niche 135
Fas/Fas-ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells 134
Current status of targeted therapies in advanced gastric cancer 134
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 133
Hydroxy-propil-β-cyclodextrin inclusion complexes of two biphenylnicotinamide derivatives: Formulation and anti-proliferative activity evaluation in pancreatic cancer cell models 133
CES2, ABCG2, TS and topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen 132
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 132
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice 132
Laparoscopic vs. open mesorectal excision for rectal cancer: Are these approaches still comparable? A systematic review and metaanalysis 132
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma 131
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 131
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 130
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 129
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials 129
Immunotherapy for colorectal cancer: where are we heading? 128
Advances in EGFR-directed therapy in head and neck cancer 128
High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression 127
Torch study: How much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer? 126
The process of truth disclosure: An assessment of the results of information during the diagnostic phase in patients with cancer 125
Totale 16.414
Salva come PNG Salva come JPEG
Categoria #
all - tutte 142.076
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 142.076
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.822 0 0 40 77 159 149 109 133 141 111 223 680
2022/20233.663 397 511 290 357 314 410 110 469 538 25 202 40
2023/20241.164 84 215 80 101 123 319 19 66 9 28 10 110
2024/20254.528 94 82 357 206 153 512 379 415 162 221 732 1.215
2025/202610.719 1.481 405 593 825 1.272 526 1.126 305 1.045 775 903 1.463
2026/20271.429 502 592 335 0 0 0 0 0 0 0 0 0
Totale 31.504